Escalon Medical Financials
This page shows Escalon Medical (ESMC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Escalon Medical has an operating margin of 1.1%, meaning the company retains $1 of operating profit per $100 of revenue. This below-average margin results in a low score of 25/100, suggesting thin profitability after operating expenses. This is up from -0.9% the prior year.
Escalon Medical's revenue grew a modest 0.5% year-over-year to $12.0M. This slow but positive growth earns a score of 34/100.
Escalon Medical carries a low D/E ratio of 1.61, meaning only $1.61 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 69/100, indicating a strong balance sheet with room for future borrowing.
Escalon Medical's current ratio of 1.72 indicates adequate short-term liquidity, earning a score of 30/100. The company can meet its near-term obligations, though with limited headroom.
Escalon Medical has a free cash flow margin of 3.1%, earning a moderate score of 33/100. The company generates positive cash flow after capital investments, but with room for improvement.
Escalon Medical generates a 5.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 23/100. This is up from -6.9% the prior year.
Escalon Medical scores -15.99, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.2M) relative to total liabilities ($3.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Escalon Medical passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Escalon Medical generates $3.61 in operating cash flow ($381K OCF vs $106K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Escalon Medical earns $5.9 in operating income for every $1 of interest expense ($133K vs $23K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Escalon Medical generated $12.0M in revenue in fiscal year 2025. This represents an increase of 0.5% from the prior year.
Escalon Medical's EBITDA was $171K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 392.6% from the prior year.
Escalon Medical reported $106K in net income in fiscal year 2025. This represents an increase of 184.2% from the prior year.
Escalon Medical earned $0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.0% from the prior year.
Cash & Balance Sheet
Escalon Medical generated $377K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 158.6% from the prior year.
Escalon Medical held $546K in cash against $0 in long-term debt as of fiscal year 2025.
Escalon Medical had 7M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
Escalon Medical's gross margin was 45.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.8 percentage points from the prior year.
Escalon Medical's operating margin was 1.1% in fiscal year 2025, reflecting core business profitability. This is up 2.0 percentage points from the prior year.
Escalon Medical's net profit margin was 0.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.9 percentage points from the prior year.
Escalon Medical's ROE was 5.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 12.4 percentage points from the prior year.
Capital Allocation
Escalon Medical invested $753K in research and development in fiscal year 2025. This represents an increase of 9.4% from the prior year.
Escalon Medical invested $4K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 90.4% from the prior year.
ESMC Income Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2K-100.0% | $3.6M+34.2% | $2.7M+4.1% | $2.6M-26.0% | $3.5M+7.9% | $3.2M+15.8% | $2.8M-19.9% | $3.5M |
| Cost of Revenue | $2.0M0.0% | $2.0M+30.9% | $1.6M+7.5% | $1.4M-22.8% | $1.9M+13.8% | $1.6M+5.0% | $1.6M-21.6% | $2.0M |
| Gross Profit | -$2.0M-230.7% | $1.6M+38.8% | $1.1M-0.3% | $1.1M-29.7% | $1.6M+1.6% | $1.6M+29.7% | $1.2M-17.6% | $1.5M |
| R&D Expenses | $131K0.0% | $131K-39.3% | $216K-25.9% | $292K+77.0% | $165K+5.7% | $156K+10.7% | $141K-18.6% | $173K |
| SG&A Expenses | $1.3M0.0% | $1.3M+19.8% | $1.1M-8.0% | $1.2M+3.9% | $1.2M-0.3% | $1.2M+5.7% | $1.1M-5.3% | $1.2M |
| Operating Income | $99K0.0% | $99K+148.7% | -$203K+45.5% | -$372K-234.7% | $276K+7.9% | $256K+1049.4% | -$27K-119.5% | $138K |
| Interest Expense | $7760.0% | $776-82.0% | $4K-46.1% | $8K+74.9% | $5K-6.5% | $5K-7.2% | $5K+35.0% | $4K |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $98K0.0% | $98K+140.7% | -$240K+36.8% | -$380K-239.9% | $271K+10.3% | $246K+863.6% | -$32K-124.0% | $134K |
| EPS (Diluted) | $0.010.0% | $0.01+133.3% | $-0.03 | N/A | $0.020.0% | $0.02+300.0% | $-0.01 | N/A |
ESMC Balance Sheet
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.0M0.0% | $5.0M+8.7% | $4.6M-8.2% | $5.0M-4.3% | $5.2M+16.2% | $4.5M-4.9% | $4.7M-0.8% | $4.8M |
| Current Assets | $4.3M0.0% | $4.3M+1.6% | $4.2M-8.4% | $4.6M-4.8% | $4.8M+12.5% | $4.3M-3.2% | $4.4M+1.2% | $4.4M |
| Cash & Equivalents | $337K0.0% | $337K-45.2% | $616K+12.8% | $546K-31.6% | $797K+53.2% | $521K+126.6% | $230K+9.9% | $209K |
| Inventory | $1.5M0.0% | $1.5M-12.7% | $1.7M-18.5% | $2.1M+22.8% | $1.7M+1.5% | $1.7M-4.8% | $1.8M+11.9% | $1.6M |
| Accounts Receivable | $2.2M0.0% | $2.2M+67.4% | $1.3M-11.0% | $1.5M-29.4% | $2.1M+32.2% | $1.6M-16.6% | $1.9M-9.1% | $2.1M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.2M0.0% | $3.2M+10.3% | $2.9M-5.6% | $3.1M+5.4% | $2.9M+18.6% | $2.5M-16.3% | $2.9M-0.2% | $2.9M |
| Current Liabilities | $2.6M0.0% | $2.6M+2.9% | $2.5M-5.8% | $2.7M+6.6% | $2.5M+13.9% | $2.2M-17.5% | $2.7M+0.5% | $2.7M |
| Long-Term Debt | $141K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.8M0.0% | $1.8M+5.8% | $1.7M-12.5% | $1.9M-16.5% | $2.3M+13.4% | $2.0M+13.8% | $1.8M-1.8% | $1.8M |
| Retained Earnings | $68.6M+200.0% | -$68.6M+0.1% | -$68.7M-0.4% | -$68.4M-0.6% | -$68.1M+0.4% | -$68.3M+0.4% | -$68.6M0.0% | -$68.5M |
ESMC Cash Flow Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $432K+183.6% | -$517K-708.7% | $85K+439.4% | $16K-48.7% | $31K-89.8% | $301K+802.9% | $33K+109.8% | -$340K |
| Capital Expenditures | $4K | $0-100.0% | $4K+13.9% | $4K | $0 | $0 | $0-100.0% | $9K |
| Free Cash Flow | $428K+182.7% | -$517K-742.1% | $81K+578.3% | $12K-61.3% | $31K-89.8% | $301K+802.9% | $33K+109.5% | -$349K |
| Investing Cash Flow | $4K | $0+100.0% | -$4K-13.9% | -$4K | $0 | $0 | $0+100.0% | -$9K |
| Financing Cash Flow | $28K+260.5% | -$18K-65.3% | -$11K-53.1% | -$7K+33.1% | -$10K-3.2% | -$10K+20.7% | -$13K-93.7% | -$7K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ESMC Financial Ratios
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -117757.3%-117800.6pp | 43.3%+1.4pp | 41.9%-1.9pp | 43.7%-2.3pp | 46.1%-2.8pp | 48.9%+5.3pp | 43.6%+1.2pp | 42.4% |
| Operating Margin | 5717.3%+5714.6pp | 2.8%+10.3pp | -7.6%+6.9pp | -14.5%-22.4pp | 8.0%0.0pp | 8.0%+8.9pp | -1.0%-5.0pp | 4.0% |
| Net Margin | 5655.9%+5653.2pp | 2.7%+11.7pp | -9.0%+5.8pp | -14.8%-22.6pp | 7.8%+0.2pp | 7.6%+8.8pp | -1.2%-5.0pp | 3.9% |
| Return on Equity | 5.5%0.0pp | 5.5%+19.8pp | -14.3%+5.5pp | -19.8%-31.7pp | 11.8%-0.3pp | 12.2%+14.0pp | -1.8%-9.2pp | 7.4% |
| Return on Assets | 2.0%0.0pp | 2.0%+7.2pp | -5.2%+2.4pp | -7.6%-12.8pp | 5.2%-0.3pp | 5.5%+6.2pp | -0.7%-3.5pp | 2.8% |
| Current Ratio | 1.650.0 | 1.65-0.0 | 1.67-0.0 | 1.72-0.2 | 1.92-0.0 | 1.95+0.3 | 1.66+0.0 | 1.65 |
| Debt-to-Equity | 0.08-1.7 | 1.81+0.1 | 1.73+0.1 | 1.61+0.3 | 1.27+0.1 | 1.22-0.4 | 1.66+0.0 | 1.63 |
| FCF Margin | 24782.0%+24796.5pp | -14.4%-17.4pp | 3.0%+2.5pp | 0.5%-0.4pp | 0.9%-8.5pp | 9.3%+8.1pp | 1.2%+11.3pp | -10.1% |
Frequently Asked Questions
What is Escalon Medical's annual revenue?
Escalon Medical (ESMC) reported $12.0M in total revenue for fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Escalon Medical's revenue growing?
Escalon Medical (ESMC) revenue grew by 0.5% year-over-year, from $12.0M to $12.0M in fiscal year 2025.
Is Escalon Medical profitable?
Yes, Escalon Medical (ESMC) reported a net income of $106K in fiscal year 2025, with a net profit margin of 0.9%.
What is Escalon Medical's EBITDA?
Escalon Medical (ESMC) had EBITDA of $171K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Escalon Medical's gross margin?
Escalon Medical (ESMC) had a gross margin of 45.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Escalon Medical's operating margin?
Escalon Medical (ESMC) had an operating margin of 1.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Escalon Medical's net profit margin?
Escalon Medical (ESMC) had a net profit margin of 0.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Escalon Medical's return on equity (ROE)?
Escalon Medical (ESMC) has a return on equity of 5.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Escalon Medical's free cash flow?
Escalon Medical (ESMC) generated $377K in free cash flow during fiscal year 2025. This represents a 158.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Escalon Medical's operating cash flow?
Escalon Medical (ESMC) generated $381K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Escalon Medical's total assets?
Escalon Medical (ESMC) had $5.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Escalon Medical's capital expenditures?
Escalon Medical (ESMC) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Escalon Medical spend on research and development?
Escalon Medical (ESMC) invested $753K in research and development during fiscal year 2025.
What is Escalon Medical's current ratio?
Escalon Medical (ESMC) had a current ratio of 1.72 as of fiscal year 2025, which is generally considered healthy.
What is Escalon Medical's debt-to-equity ratio?
Escalon Medical (ESMC) had a debt-to-equity ratio of 1.61 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Escalon Medical's return on assets (ROA)?
Escalon Medical (ESMC) had a return on assets of 2.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Escalon Medical's Altman Z-Score?
Escalon Medical (ESMC) has an Altman Z-Score of -15.99, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Escalon Medical's Piotroski F-Score?
Escalon Medical (ESMC) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Escalon Medical's earnings high quality?
Escalon Medical (ESMC) has an earnings quality ratio of 3.61x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Escalon Medical cover its interest payments?
Escalon Medical (ESMC) has an interest coverage ratio of 5.9x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Escalon Medical?
Escalon Medical (ESMC) scores 36 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.